Last €11.47 EUR
Change Today -0.196 / -1.68%
Volume 0.0
A5I On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:20 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

atricure inc (A5I) Snapshot

Open
€11.47
Previous Close
€11.67
Day High
€11.47
Day Low
€11.47
52 Week High
01/20/14 - €16.49
52 Week Low
04/19/13 - €5.69
Market Cap
314.4M
Average Volume 10 Days
3.5
EPS TTM
--
Shares Outstanding
27.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATRICURE INC (A5I)

Related News

No related news articles were found.

atricure inc (A5I) Related Businessweek News

No Related Businessweek News Found

atricure inc (A5I) Details

AtriCure, Inc., a medical device company, provides atrial fibrillation solutions worldwide. It provides isolator bipolar radio-frequency (RF) ablation clamps that are used for ablation during open-heart procedures; and ablation and sensing unit, a compact power generator that provides the RF energy for its clamps, multifunctional pens, and coolrail linear ablation devices. The company also offers AtriCure Switch Box, a compact switch box, which offers the technology needed for the dual pulsing electrodes in isolator synergy clamps; isolator multifunctional pens that enable surgeons to evaluate cardiac arrhythmias, as well as to perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and coolrail linear ablation device, a disposable linear RF ablation device that allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. In addition, it provides RF ablation devices, such as COBRA Fusion Surgical Ablation System; COBRA Revolution Bipolar Clamp; COBRA Electrosurgical Unit; COBRA Monopolar Surgical Devices; and COBRA AFfirm Bipolar Pacing Probe. Further, the company offers cryoablation system, which is used for afib ablation treatment during certain open-heart procedures; and AtriClip System that is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures. Additionally, it sells technologies, including Lumitip dissector to separate tissues to provide access to anatomical structures that are targeted for ablation; the MicroPace ORLab system, a stimulating, mapping, and recording system; and Estech valve surgical devices that provide solutions with exposure and instrumentation for valve procedures using minimally invasive access. The company sells its products to hospitals and medical centers through independent distributors and direct sales personnel. AtriCure, Inc. is headquartered in West Chester, Ohio.

320 Employees
Last Reported Date: 03/11/14

atricure inc (A5I) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $212.5K
Senior Vice President of Operations & Quality...
Total Annual Compensation: $278.1K
Vice President and General Manager of Interna...
Total Annual Compensation: $378.8K
Senior Vice President of Sales & Marketing
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

atricure inc (A5I) Key Developments

AtriCure, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Earnings Guidance for Fiscal 2014

AtriCure, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenue of $21,884,000 compared to $18,364,000 for the same period a year ago. Loss from operations was $4,838,000 compared to $1,852,000 for the same period a year ago. Loss before income tax expense was $4,976,000 compared to $1,990,000 for the same period a year ago. Net loss was $4,980,000 compared to $2,020,000 for the same period a year ago. Basic and diluted net loss per share was $0.24 compared to $0.12 for the same period a year ago. Non-GAAP adjusted loss (adjusted EBITDA) was $3,275,000 compared to $946,000 for the same period a year ago. For the full year, the company reported total revenue of $81,889,000 compared to $70,247,000 for the same period a year ago. Loss from operations was $10,891,000 compared to $7,198,000 for the same period a year ago. Loss before income tax expense was $11,444,000 compared to $7,484,000 for the same period a year ago. Net loss was $11,462,000 compared to $7,534,000 for the same period a year ago. Basic and diluted net loss per share was $0.56 compared to $0.47 for the same period a year ago. Net cash used in operating activities was $5,222,000 compared to $1,936,000 for the same period a year ago. Purchases of property and equipment were $2,864,000 compared to $2,985,000 for the same period a year ago. Non-GAAP adjusted loss (adjusted EBITDA) was $5,791,000 compared to $1,831,000 for the same period a year ago. The company projected that 2014 revenue will be in the range of $100 million to $103 million, which represents an increase of 22% to 26% over 2013. Organic revenue growth is expected to be approximately 13% to 15% with the remaining portion expected from the recently acquired Estech ablation and valve products. Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $9 million to $10 million for 2014, of which approximately $3.5 million of expense will be related to the Estech transaction.

AtriCure, Inc., Q4 2013 Earnings Call, Feb 27, 2014

AtriCure, Inc., Q4 2013 Earnings Call, Feb 27, 2014

AtriCure, Inc. to Report Q4, 2013 Results on Feb 27, 2014

AtriCure, Inc. announced that they will report Q4, 2013 results at 8:01 PM, GMT Standard Time on Feb 27, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
A5I:GR €11.47 EUR -0.196

A5I Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Hansen Medical Inc $2.30 USD +0.07
InspireMD Inc $2.46 USD +0.10
LeMaitre Vascular Inc $7.99 USD 0.00
Stereotaxis Inc $3.60 USD -0.05
Spectranetics Corp $24.23 USD +1.15
View Industry Companies
 

Industry Analysis

A5I

Industry Average

Valuation A5I Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 5.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATRICURE INC, please visit www.atricure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.